Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S271000, C544S272000, C514S217050, C540S575000
Reexamination Certificate
active
07074798
ABSTRACT:
The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect.The compounds are represented by the formula:wherein, m is 0 or 1;n is 0;R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, and R42each represent a hydrogen atom;X represents an alkynyl group, an aryl group, and such, which group may be substituted; and,R1and R2each independently represents a hydrogen atom, an alkyl group, an alkoxyl group, or such,or salts or hydrates thereof.
REFERENCES:
patent: 3896119 (1975-07-01), Klingler
patent: 6011155 (2000-01-01), Villhauer
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 2001/0020006 (2001-09-01), Demuth et al.
patent: 2002/0161001 (2002-10-01), Kanstrup et al.
patent: 2002/0198205 (2002-12-01), Himmelsbach et al.
patent: 2003/0199528 (2003-10-01), Kanstrup et al.
patent: 2004/0077645 (2004-04-01), Himmelsbach et al.
patent: 2004/0118328 (2004-06-01), Yoshikawa et al.
patent: 101 09 021 (2002-09-01), None
patent: 101 17 803 (2002-10-01), None
patent: 1054012 (2000-11-01), None
patent: 1 308 439 (2003-05-01), None
patent: 1 323 710 (2003-07-01), None
patent: 1 333 025 (2003-08-01), None
patent: 1 338 595 (2003-08-01), None
patent: 1 338 595 (2003-08-01), None
patent: 1 354 882 (2003-10-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 00/56296 (2000-09-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/14271 (2002-02-01), None
patent: WO 02/30890 (2002-04-01), None
patent: WO 02/38541 (2002-05-01), None
patent: WO 02/051836 (2002-07-01), None
patent: WO 02/062764 (2002-08-01), None
patent: WO 02/68420 (2002-09-01), None
patent: WO 02/076450 (2002-10-01), None
patent: WO 02/083128 (2002-10-01), None
patent: WO 03/004496 (2003-01-01), None
patent: WO 03/104229 (2003-12-01), None
patent: WO 2004/028524 (2004-04-01), None
patent: WO 2004/050656 (2004-06-01), None
Balkan, et al. “Inhibition of Dipeptidyl Peptidase IV with NVP-DPP728 Increases Plasma GLP-1 (7-36 Amide) Concentrations and Improves Oral Glucose Tolerance in Obese Zucker Rats.”Diabetologia, vol. 42, No. 11, pp. 1324-1331. Springer-Verlag. 1999.
Bauvois, et al. “Constitutive Expression of CD26/Dipeptidylpeptidase IV on Peripheral Blood B Lymphocytes of Patients with B Chronic Lymphocytic Leukaemia.”British Journal of Cancer, vol. 79, No. 7-8, pp. 1042-1048. 1999.
Callebaut, et al. “T Cell Activation Antigen, CD26, as a Cofactor for Entry of HIV In CD4+Cells.”Science, vol. 262, No. 5142, pp. 2045-2050. 1993.
Gotoh, et al. “Activity of Dipeptidyl Peptidase IV and Post-Proline Cleaving Enzyme in Sera from Osteoporotic Patients.”Clinical Chemistry, vol. 34, No. 12, pp. 2499-2501. 1988.
Hartmann, et al. “Dipeptidyl Peptidase IV Inhibition Enhances the Intestinotrophic Effect of Glucagon-Like Peptide-2 in Rats and Mice.”Endocrinology, vol. 141, No. 11, pp. 4013-4020. 2000.
Holst, et al. “Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes.”Diabetes, vol. 47, No. 11, pp. 1663-1670. 1998.
Kohl, et al. “The Role of Dipeptidylpeptidase IV Positive T Cells in Wound Healing and Angiogenesis.”Agents and Actions, vol. 32, No. 1/2, pp. 125-127. Birkhäuser Verlag, Basel. 1991.
Steinbrecher, et al. “Targeting Dipeptidyl Peptidase IV (CD26) Suppresses Autoimmune Encephalomyelitis and Up-Regulates TGF-β1 Secretion In Vivo.”The Journal of Immunology, vol. 166, No. 3, pp. 2041-2048. 2001.
Wilson, et al. “Dipeptidylpeptidase IV Activities are Elevated in Prostate Cancers and Adjacent Benign Hyperplastic Glands.”Journal of Andrology, vol. 21, No. 2, pp. 220-226. 2000.
Yip, et al. “Minireview: GIP Biology and Fat Metabolism.”Life Sciences, vol. 66, No. 2, pp. 91-103. Elsevier Science Inc., USA. 2000.
Augustyns, K., et al., “The Unique Properties of Dipeptidyl-Peptidase IV (DPP IV/CD26) and the Therapeutic Potential of DPP IV Inhibitors”,Current Medicinal Chemistry(1999) vol. 6, No. 4.
Translation of WO 03/104229.
Translation of WO 2004/050656.
Translation of WO 2004/028524.
Aoki Mika
Clark Richard
Emori Eita
Ikuta Hironori
Matsuura Fumiyoshi
Berch Mark L.
Eisai Co., Ltd
LandOfFree
Xanthine derivative and DPPIV inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Xanthine derivative and DPPIV inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Xanthine derivative and DPPIV inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3535910